| Oct 22 |
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know
|
| Oct 22 |
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
|
| Oct 15 |
Best Momentum Stocks to Buy for October 15th
|
| Oct 2 |
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
|
| Sep 23 |
PDS Biotechnology: Continuing The Holding Pattern
|
| Sep 16 |
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
|
| Sep 9 |
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
|
| Sep 3 |
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 13 |
PDS Biotechnology: Q2 Earnings Snapshot
|
| Aug 13 |
PDS Biotechnology GAAP EPS of -$0.23 beats by $0.10
|
